Parameters for cost effectiveness model
| Parameter | Pembrolizumab | Placebo | Distribution | ||
| Value | Ranges | Value | Ranges | ||
| Probabilities | |||||
| PFS (Weibull) | |||||
| Scale(λ) | 0.0448 | 0.0876 | |||
| Shape(γ) | 1.2675 | 1.2312 | |||
| OS(exponential) | |||||
| Scale(λ) | 0.0290 | 0.0586 | |||
| Costs ($) | |||||
| Pembrolizumab/mg16 | 48.57 | +/-25% | 48.57 | +/-25% | Lognorm |
| Pemetrexed/mg16 | 6.75 | +/-25% | 6.75 | +/-25% | Lognorm |
| Cisplatin/mg16 | 0.20 | +/-25% | 0.20 | +/-25% | Lognorm |
| Carboplatin/mg16 | 0.06 | +/-25% | 0.06 | +/-25% | Lognorm |
| Chemotherapy infusion 1 hour16 | 145 | +/-25% | 145 | +/-25% | Lognorm |
| Chemotherapy infusion additional hour16 | 32 | +/-25% | 32 | +/-25% | Lognorm |
| Subsequent therapies/cycle16 | 1160 | +/-25% | 4394 | +/-25% | Lognorm |
| End-of-life care14 | 33 009 | +/-25% | 33 009 | +/-25% | Lognorm |
| AE hospitalisation cost13 | 3538 | +/-50% | 3005 | +/-50% | Lognorm |
| Baseline utilities | |||||
| PFS19 | 0.71 | 0.67–0.76 | 0.71 | 0.67–0.76 | Beta |
| disease progression survival19 | 0.67 | 0.59–0.75 | 0.67 | 0.59–0.75 | Beta |
| Disutilities | |||||
| Neutropenia20 | 0.09 | 0.060–0.119 | 0.09 | 0.060–0.119 | Beta |
| Pneumonia20 | 0.09 | 0.059–0.121 | 0.09 | 0.059–0.121 | Beta |
AE, adverse effect; OS, overall survival;PFS, progression-free survival.